Filing Details
- Accession Number:
- 0001209191-19-043918
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-07-31 19:14:02
- Reporting Period:
- 2019-07-30
- Accepted Time:
- 2019-07-31 19:14:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 914475 | Neurocrine Biosciences Inc | NBIX | Biological Products, (No Disgnostic Substances) (2836) | 330525145 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1504783 | Darin Lippoldt | 12780 El Camino Real San Diego CA 92130 | Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-07-30 | 15,831 | $18.15 | 35,792 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-07-30 | 15,831 | $92.13 | 19,961 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option | Disposition | 2019-07-30 | 15,831 | $18.15 | 15,831 | $18.15 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-11-03 | No | 4 | M | Direct |
Footnotes
- Includes 315 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2019.
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $91.39 to $94.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- Represents option which vested 1/4 upon anniversary of grant (11/3/2014), thereafter vested in equal monthly installments over the following three years such that the entire award was fully vested at 11/3/2018.
Billionaire Hedge Funds
